PCI Pharma Services (PCI) has premiered its new contained packaging facility for the primary and secondary packaging of highly potent products at its newly acquired site near Dublin, Ireland. This latest investment further demonstrates PCI’s ability to provide its current and future customers with the highest standards of excellence in outsourced pharmaceutical packaging services.
PCI manufactures highly potent molecules at its purpose built, contained manufacturing facility located at its Tredegar site in Wales. This latest investment in contained packaging capabilities at the PCI Ireland site ensures its on-going commitment to delivering the highest standards of safety and regulatory adherence for specialised medicines. It is also the most recent part of PCI’s strategic initiative to develop its High Containment Operations (HCO) services globally.
‘We are very excited to officially launch our state of the art high contained packaging facility here in Ireland,’ commented Bill Mitchell, president and CEO. ‘The recent acquisition of Millmount Healthcare and further investment in this newest specialised facility adds considerable capacity and capability to our global supply network, enabling us to meet our customers’ ever changing and evolving needs in many different geographies. Moreover, as our fourth acquisition outside the US in the past four years, this expansion further demonstrates our ability to provide our clients with a comprehensive solution to any uncertainty brought upon by on-going negotiations between the UK and EU as a result of the evolving Brexit situation.’